Entering text into the input field will update the search result below

Aastrom (ASTM) Manufacturing Transfer and CLI Product Naming

Apr. 04, 2011 12:36 PM ET1 Comment
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Long/Short Equity, Special Situations, Contrarian

Seeking Alpha Analyst Since 2009

Editor and Publisher ... Henry enters his thirteen (13) year at RegMed Investors which aggregates, curates and creates bottom-line content of regenerative medicine - stem, gene and cell therapy news providing a "vetted" selection of relevant and high-impact synthesis. He was VP - Strategic Planning and Communication at Curis (2001-2002), HQCM focusing on healthcare investments (NYSE:HQH/HQL) from (1985-2001)and founded LifeScience Economics, a healthcare research and analytics firm with offices in Boston, MA and Palo Alto, CA. Past experiences include Thermo Scientific, SWEC following 5 years at the FBI. A former military officer, Henry has been an adjunct professor at Boston University and Golden Gate University where he taught courses in venture capital, corporate finance and strategic development in the universities' graduate business schools.

Manufacturing steps completed in preparation for PIII CLI Program

ASTM transferred cell cassette manufacturing to ATEK Medical under the 10/10 partnership. These single-use cell cassettes are the central component used in its proprietary culturing process at its cell manufacturing facility. Ixmyelocel-T has been formally accepted by the US FDA and the Adopted Names Council as the non-proprietary name for ASTM’s investigational cell therapy product.

The Bottom Line: Packaged noise, not milestones but, Needham & Co’s “BUY” and $6.00 price target stimulated share appreciation. However, recognize this is the press build-up pre one SPA approval which will substantiate  a … very … dilutionary offering by Needham and Stifel. Needham also came out with a “BUY” on Pluristem (PSTI), ASTM’s comparable at $5.00. Just, keeping the banking  fee “pot” warm!

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.